The sugar-free paradox:cardiometabolic consequences of erythritol  

作　　者：Kalliopi Pafili Michael Roden 

机构地区：[1]Department of Endocrinology and Diabetology,Medical Faculty and University Hospital Düsseldorf,Heinrich-Heine-University Düsseldorf,40225 Düsseldorf,Germany [2]German Center for Diabetes Research,Partner Düsseldorf,85764 München-Neuherberg,Germany [3]Institute for Clinical Diabetology,German Diabetes Center,Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf,40225 Düsseldorf,Germany

出　　处：《Signal Transduction and Targeted Therapy》2023年第7期3200-3202,共3页信号转导与靶向治疗（英文）

基　　金：The authors are supported in part by the German Diabetes Center(DDZ),which is funded by the Ministry of Culture and Science of the State of Northrhine Westphalia and the German Federal Ministry of Health(BMG),by grants of the Federal Ministry for Research(BMBF)to the German Center for Diabetes Research(DZD e.V.,DZD Grant 2016);M.R.is also supported by grants from the European Funds for Regional Development(EFRE-0400191);the German Research Foundation(DFG,SFB 1116/2,GRK 2576);the Schmutzler-Stiftung and the European Community(HORIZON-HLTH2022-STAYHLTH-02-01:Panel A)to the INTERCEPT-T2D consortium.

摘　　要：In a recent study published in Nature Medicine,Witkowski and colleagues applied untargeted metabolomics studies in 1157 people at high risk for cardiovascular disease,comprising 22%with diabetes mellitus,followed by quantitative targeted analyses to identify circulating metabolites associated with an increased cardiovascular risk.

关 键 词：CARDIOVASCULAR TARGETED Medicine 

分 类 号：R587.1[医药卫生—内分泌]